LimeLight of The week is
 

Lexaria Bioscience Corp.
(NASDAQ: LEXX)

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 23 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

Investment Considerations

• Lexaria Bioscience Corp. has disruptive proprietary technology protected by a broad international patent portfolio.
• The company has been issued 23 patents in the U.S., European Union and other countries, with more than 50 patents pending around the world.
• Lexaria’s DehydraTECH technology has a vast worldwide, multi-billion-dollar total addressable market, including multiple rapid-growth segments like cannabinoid and noncombustible nicotine delivery.
• The company has licensed its fat-soluble active molecule delivery technology to multiple established companies for use in their products.
• Lexaria completed an uplisting to Nasdaq Capital Markets and an $11 million financing in January 2021.

Recent Coverage

CannabisNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, blood pressure findings from HYPER-H21-3 will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4. The study protocols for HYPER-H21-4 are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. HYPER-H21-4, which will be more comprehensive than Lexaria’s previous studies, is expected to involve 60 different volunteers aged between 45 and 70 years. Each of them will use three 150 mg doses of DehydraTECH-CBD every day over six weeks. A recent article notes, “The eventual goal is to seek regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure, and data from this study could be instrumental to that pursuit.”

To view the full article, visit https://cnw.fm/3cpKW

Receive SMS Text Alerts from CannabisNewsWire

Text "Cannabis" to 21000

(US Mobile Phones Only)

Featured Event

NCIA's 7th Annual Cannabis Business Summit & Expo
San Francisco; 12/15/21 - 12/17/21

The Cannabis Business Summit & Expo, hosted by the National Cannabis Industry Association, is the industry’s most significant national B2B trade exhibition and the only event that brings together an exclusive lineup of education, exhibitors, and experiences under one roof. Over 125 speakers, more than 80 educational sessions, and 300+ exhibitors will be featured at the #CannaBizSummit 2021.

Furthermore, at mixers and happy hours, event guests from throughout the country, including licensed merchants, cultivators, cannabis sector business owners, and consumer enthusiasts, will have the opportunity to form significant connections with fellow professionals.

The event also marks the premiere of BLOOM, a “show within a show” that will provide participants with a truly immersive sensory experience by allowing them to view, touch, and smell products from dozens of firms specializing in flower, vapor, pre-roll, oils, edibles, and more right on the show floor.

For more details, please visit https://ibn.fm/ZUMXO.

Conference Highlights

• On a 12,000 square foot show floor, the #CannaBizSummit will feature over 125 speakers, over 80 educational sessions, and 300+ exhibitors.
• Cannabis business leaders and activists Troy Datcher, Marvin Washington, Rachael Rapinoe, and Anna Symonds will be the speakers.
• Join offsite tours and see first-hand how other dispensaries and cultivation facilities are delivering quality products and services for their customers.

Upcoming Events

• Alternative Products Expo, Fort Lauderdale - Ft. Lauderdale, FL; 3/11/22 - 3/13/22
• NECANN’s Boston Convention - Boston, MA; 3/18/22 - 3/20/22
• Alternative Products Expo, Colombia - Colombia; 5/21/22 - 5/22/22

About CannabisNewsWire (CNW)

CannabisNewsWire (CNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CNW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CNW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CNW is where news, content and information converge.